Listen
Reason for request
Reassessment of the Actual Benefit of all medicines indicated in hormone replacement therapy for menopause at the request of the Committee, pursuant to Article R-163-21 of the French Social Security Code and Renewal of inclusion
-
Clinical Benefit
| Substantial |
The actual benefit of the proprietary medicinal product CLIMARA remains substantial in the prevention of postmenopausal osteoporosis in women at increased risk of osteoporotic fracture and who are intolerant to or contraindicated for the other treatments indicated for the prevention of osteoporosis in the event of climacteric disorders and recent menopause, after a minor fracture or if there is a low T-score, when this proprietary medicinal product is used as per the Committee's recommendations. |
Therapeutic use
- |
